Riskpilot← Back to searchSign inGet full accessPolypeptide Laboratories Holding (PPL) AB
ABActiveOrg 5564995099Soldattorpsv 5Activities of holding companies · NACE 6421Est. 19940 employees
Revenue 2024
SEK 1,8B
+5% vs 2023
EBITDA margin
-17.1%
+48% vs 2023
Equity ratio
6.7%
Financial strength
Net profit 2024
SEK -102,2M
+23% vs 2023
| Revenue | SEK 1,8B | +5% |
| EBITDA | SEK -310,3M | +48% |
| Net profit | SEK -102,2M | +23% |
| Total assets | SEK 4,9B | +11% |
| Equity | SEK 325,7M | -21% |
| Employees | 0 | — |
Legal name
Polypeptide Laboratories Holding (PPL) AB
Org number
5564995099
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
23 december 1994
Share capital
SEK 206 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget har till föremål för sin verksamhet att tillverka, utveckla och idka handel med peptider och därpå baserade kemisk-tekniska produkter, att förvärva och upplåta licenser och agenturer för sådana produkter, att idka därmed förenlig verksamhet samt att idka finansiell verksamhet, dock ej sådan verksamhet som avses i lag om bankrörelse eller lag om kreditaktiebolag. Bolaget har vidare till föremål för sin verksamhet att äga och förvalta värdepapper samt att idka därmed förenlig verksamhet.
Address
Soldattorpsv 5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 709 254 | 892 176 | 1 325 018 | 1 733 805 | 1 812 711 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −27 173 | −36 901 | −189 705 | −595 311 | −310 298 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | −27 173 | −36 901 | −189 705 | −595 311 | −310 298 |
| Net financials | −20 680 | −11 798 | −26 646 | 258 770 | −38 008 |
| Profit before tax | 8 338 | 39 340 | 8 019 | −235 402 | −96 405 |
| Tax | −4 796 | −8 210 | −2 569 | 103 304 | −5 798 |
| Net profit | 3 542 | 31 130 | 5 450 | −132 098 | −102 203 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 474 872 | 2 025 398 | 2 993 944 | 4 385 450 | 4 876 652 |
| Equity | 466 123 | 499 774 | 547 704 | 414 336 | 325 688 |
| Long-term debt | 342 441 | 695 063 | 1 596 279 | 2 661 775 | 2 460 866 |
| Short-term debt | 666 308 | 830 561 | 849 961 | 1 309 339 | 2 090 099 |
| Total debt | 1 008 749 | 1 525 624 | 2 446 240 | 3 971 114 | 4 550 965 |
EBITDA margin
-17.1%
This company
15.8%
Market median
-208% vs market
20202024
Equity ratio
6.7%
This company
38.2%
Market median
-82% vs market
20202024
Return on equity
-31.4%
This company
18.4%
Market median
-271% vs market
20202024
Net profit margin
-5.6%
This company
8.1%
Market median
-169% vs market
20202024
Asset turnover
0.37×
This company
1.12×
Market median
-67% vs market
20202024
Debt / equity
13.97×
This company
0.62×
Market median
-2153% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SE Chief Auditor | Chief Auditor | 2024 |
| Former (6) | ||
JC External Signatory | External Signatory | 2020 – 2022 |
FF External Signatory | External Signatory | 2020 – 2021 |
JA Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
DG External Signatory | External Signatory | 2020 – 2022 |
SJ Chief Auditor | Chief Auditor | 2020 – 2024 |
LP Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Chairman | 2022 | |
| Former (6) | ||
| Chairman | 2023 – 2023 | |
| Deputy Board Member | 2022 – 2025 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2020 – 2022 | |
| Board of Directors | 2022 – 2025 | |
| Chairman | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
POLYPEPTIDE GROUP AG
Polypeptide Laboratories Holding (PPL) AB (this company)Polypeptide Laboratories France SasPolypeptide Laboratories IncPolypeptide Laboratories Pvt LtdPolypeptide Laboratories A/SPOLYPEPTIDE LABORATORIES INCPolypeptide SaPOLYPEPTIDE LABORATORIES A/SPOLYPEPTIDE LABORATORIES PVT LTDPOLYPEPTIDE SAPOLYPEPTIDE LABORATORIES FRANCE SASBoard members of Polypeptide Laboratories Holding (PPL) AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Christensen | External Signatory | 0 companies |
| Folke Flateland | External Signatory | 0 companies |
| Jane Anne Salik | Chief Executive Officer | 0 companies |
| Sara Elisabet Königslehner | Chief Auditor | 0 companies |
| Daniel Gérard M Lasanow | External Signatory | 0 companies |
| Sven Jakob Tenselius | Chief Auditor | 0 companies |
| Lars-Göran Peter Nilsson | Deputy Chief Executive Officer | 0 companies |
| Lena Elisabeth Berdén | Deputy Board Member | 0 companies |
| Raoul Bernhardt | Board of Directors | 0 companies |
| Jan Fuhr Miller | Chairman | 0 companies |
| Viveka Maria Persson | Deputy Board Member | 0 companies |
| Erik Henricus Schropp | Board of Directors | 0 companies |
| Juan Jose Gonzalez Casanova | Chairman | 0 companies |
| Jeffrey David Hobbs | Chairman | 0 companies |
| Jens Fricke | Board of Directors | 0 companies |
| Raymond Gopal De Vré | Chairman | 0 companies |